Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab

SIMPLE SUMMARY: Diffuse large B-cell lymphoma (DLBCL) is the most common high-grade non-Hodgkin lymphoma. The current treatment combining the anti-CD20 monoclonal antibody rituximab with chemotherapy is the gold standard for frontline treatment. Although the results for patients who relapse had been...

Descripción completa

Detalles Bibliográficos
Autores principales: Papageorgiou, Sotirios G., Thomopoulos, Thomas P., Liaskas, Athanasios, Vassilakopoulos, Theodoros P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026383/
https://www.ncbi.nlm.nih.gov/pubmed/35454825
http://dx.doi.org/10.3390/cancers14081917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026383/
https://www.ncbi.nlm.nih.gov/pubmed/35454825
http://dx.doi.org/10.3390/cancers14081917

Ejemplares similares